SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Interest & Investment Income came in at $1.0 million in Q1 2026, up 1575.57% YoY from $62498.0 in Q1 2025, and up 49.44% on a QoQ basis from $700739.0 in Q4 2025.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Interest & Investment Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Interest & Investment Income data on file, last reported at $1.0 million in Q1 2026.
- Quarterly Interest & Investment Income rose 1575.57% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 184.12% YoY) and the FY2025 annual result came in at $1.4 million, up 11.36% from the prior year.
- Interest & Investment Income advanced to $1.0 million in Q1 2026, from $700739.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $1.0 million in Q1 2026 to a low of $7933.0 in Q1 2022.
- A 5-year average of $260074.4 and a median of $62498.0 in 2025 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2024 — Interest & Investment Income soared 1829.64% — and 2025, when it plunged 96.38%.
- Tracing SABS's Interest & Investment Income over 5 years: stood at $29929.0 in 2022, then surged by 1517.31% to $484046.0 in 2023, then tumbled by 71.83% to $136374.0 in 2024, then soared by 413.84% to $700739.0 in 2025, then jumped by 49.44% to $1.0 million in 2026.
- The last three Interest & Investment Income figures came in at $1.0 million (Q1 2026), $700739.0 (Q4 2025), and $655233.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | SAB Biotherapeutics | 295.88 Mn | 295.88 Mn | - | 1.71 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.71 Mn |
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | 700,739.00 |
| Sep 30, 2025 | 655,233.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 62,498.00 |
| Dec 31, 2024 | 136,374.00 |
| Sep 30, 2024 | 277,174.00 |
| Jun 30, 2024 | 374,557.00 |
| Mar 31, 2024 | 497,893.00 |
| Dec 31, 2023 | 484,046.00 |
| Sep 30, 2023 | 14,364.00 |
| Jun 30, 2023 | 28,568.00 |
| Mar 31, 2023 | 57,988.00 |
| Dec 31, 2022 | 29,929.00 |
| Sep 30, 2022 | 17,385.00 |
| Jun 30, 2022 | 15,824.00 |
| Mar 31, 2022 | 7,933.00 |
| Dec 31, 2021 | 8,544.00 |
| Sep 30, 2021 | 3,769.00 |